CO-CONTENTFUL
20.8.2024 15:01:29 CEST | Business Wire | Press release
Contentful, a leading composable content platform trusted by more than 4,200 customers, today announced it has signed a definitive agreement to acquire Berlin-based Ninetailed, the pioneer of structured content personalization and experimentation. This move will allow Contentful to offer its customers a scalable, AI-driven personalization solution that’s already integrated into the Contentful platform.
Unlike legacy solutions, the combined offering will leverage the power of composability, an API-first architecture, Generative AI, and lightning fast edge delivery. Customers will have the ability to quickly and easily identify, select, experiment, and analyze personalized experiences across channels without creating new workflows. This will enable brands to generate higher Return on Investment (ROI) from their content and data investments and ultimately increase revenue through tailored customer journeys.
“Personalization has long been a goal for marketers, but driving meaningful ROI at scale has been challenging due to fragmented tool chains, high development and content production costs, and poor customer data integration,” said Karthik Rau, Contentful’s CEO. “Ninetailed seamlessly integrates with Contentful, providing smooth workflows, code-free experiment creation, and robust connectivity. Ninetailed’s products radically simplify personalization of digital experiences.”
With an ecosystem of more than 100 integrations and plug-ins, Contentful’s scalable, reliable, enterprise-grade content platform is already the solution of choice for leading organizations. With the recent launch of Contentful Studio and the addition of Ninetailed’s products, Contentful will soon be the only solution in the market that offers a modern, composable platform tailored to technical users, combined with low-code experience-building and personalization products for marketing and design teams.
“Joining forces with Contentful means customers will benefit from a fully integrated, AI-native personalization solution paired with a robust composable content platform,” said Ninetailed co-founder and CEO Andy Kaiser. “My fellow co-founder Alexander Braunreuther, the Ninetailed team and I are beyond thrilled to be joining Contentful where we’ll have the opportunity and resources to rapidly iterate and bring category-changing innovations to market.”
Many well-known brands like Kraft Heinz, Ace & Tate and SumUp are already using Ninetailed technology in their Contentful-built digital experiences, driving higher click-through and conversion rates while reducing the time and effort it takes to bring tailored journeys to market. Direct-to-Consumer powerhouse Ruggable, another shared customer, increased its conversions by 25% and click-through rates by 7x by personalizing the landing pages for paid traffic. Ninetailed’s technology is “integral to Ruggable’s business,” said Daniel Graupensperger, the brand’s Associate Director of Product Management.
Ninetailed by Contentful will be generally available immediately after the deal closes in the coming days. Visit www.contentful.com for more information.
About Contentful
Contentful is a leading composable content platform that unlocks all of an organization’s digital content to deliver impactful customer experiences, making content a strategic business asset. The Contentful Platform, Contentful Studio, and the Contentful Ecosystem combine the flexibility of composable content with the intelligence of AI, empowering digital teams to drive business momentum through collaboration, speed, and scale. Contentful powers innovative content experiences across brands, regions, and channels for organizations of all sizes around the world. For more information, visit www.contentful.com. Contentful, the Contentful logo, and other trademarks listed here are registered trademarks of Contentful Inc., Contentful GmbH and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240820325810/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom